Souhaitez-vous accéder aux communiqués récents ?

Biotechs continue attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy pla

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth

Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naïve patients1Expedited...

STORM Therapeutics announces that a subset analysis of sarcoma patients enrolled in the Phase 1 dose escalation study of STC-15 will be presented at ASCO.

The six accepted presentations highlight clinical progress across Eikon’s pipeline.

Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2...

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancerKisqali® NATALEE oral presentation to report...

Leafwell Advances Medical Cannabis as Clinically Validated Solution for Cancer-Related Symptoms and Chronic Pain, Supports Employer-Sponsored Mental Health

Wall St analysts are rating NeOnc Technologies (NASDAQ:NTHI) a “Buy”, as institutional investors and company insiders are buying